Activity Overview
This educational activity is designed to provide expert perspectives on data presented in early 2026 regarding the use of newer anti-VEGF agents to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema related to retinal vein occlusion (RVO). As part of a panel discussion, 2 expert faculty share their insights on the relevance of these findings to patient management decisions.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, and optometrists involved in the management of patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize key 2026 conference updates that impact management of neovascular retinal disease.
- Apply evidence to select therapy and dosing strategies for nAMD based on presentation and treatment goals.
- Apply evidence to optimize management strategies for DME.
- Evaluate evidence for interval extension in RVO using emerging data.
Judy E. Kim, MD, FARVO, FASRS
Jean and Tom Walter Distinguished Chair in Ophthalmology in Honor of James P. McCulley, MD
Professor, Vitreoretinal Surgery and Diseases
Vice-Chair of Education
Medical Director of Clinical Research
University of Texas Southwestern Medical Center
Dallas, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Apellis, Bausch + Lomb, Clearside Biomedical, Coherus, Dutch Ophthalmic Research Center, Eyepoint, Genentech/Roche, Notal Vision, Outlook Therapeutics, Regeneron
Prethy Rao, MD, MPH, FACS
Adult and Pediatric Retina Specialist
Retina & Vitreous of Texas
Bellaire, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astellas, Bausch + Lomb, Eyepoint, Genentech, Regeneron; Grant/Research Funding (to institution): Regenxbio; Royalty or Patent Benefits: Vortex Surgica
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.